Therapy-Related Acute Myeloid Leukemia after CAR-T Cell Therapy with Brexucabtagene Autoleucel for Mantle Cell Lymphoma

François Volery; Yara Banz; Alexander Heini; Marie-Noelle Kronig; Daniel Siegrist; Michael Daskalakis; Ulrike Bacher; Thomas Pabst

doi:10.1159/000541256

Case Reports in Oncology (Sep 2024)

Therapy-Related Acute Myeloid Leukemia after CAR-T Cell Therapy with Brexucabtagene Autoleucel for Mantle Cell Lymphoma

François Volery,
Yara Banz,
Alexander Heini,
Marie-Noelle Kronig,
Daniel Siegrist,
Michael Daskalakis,
Ulrike Bacher,
Thomas Pabst

Affiliations

François Volery: Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
Yara Banz: Institute for Tissue Medicine and Pathology, University of Bern, Bern, Switzerland
Alexander Heini: Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
Marie-Noelle Kronig: Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
Daniel Siegrist: Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
Michael Daskalakis: Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
Ulrike Bacher: Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
Thomas Pabst: Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

DOI: https://doi.org/10.1159/000541256
Journal volume & issue: Vol. 17, no. 1
pp. 1087 – 1093

Abstract

Read online

Introduction: The introduction of CAR-T cell treatment for relapsed/refractory (r/r) mantle cell lymphoma improved survival rates of these patients. Along with its introduction in clinical routine, long-term events after CAR-T cell treatment are increasingly emerging. Case Presentation: We report the case of a patient developing acute erythroid leukemia with biallelic TP53 inactivation occurring 26 months after CAR-T therapy with brexucabtagene autoleucel (brexu-cel) for r/r mantle cell lymphoma. The patient presented with a healthy bone marrow prior to lymphoma treatments. Discussion: Secondary malignancies seem more frequent after CAR-T therapies. More studies are needed to assess potential long-term toxicities of CAR-T cell therapies including the frequency of secondary myeloid malignancies.

Published in Case Reports in Oncology

ISSN: 1662-6575 (Online)
Publisher: Karger Publishers
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.karger.com/cro

About the journal

Abstract

Keywords